前往化源商城

品牌现货直购
供应商:我要出现这里



查看所有供应商和价格请点击:

312-93-6生产厂家

312-93-6价格

312-93-6

312-93-6结构式
312-93-6结构式
  • 常用中文名:地塞米松 21-磷酸
  • 常用英文名:Dexamethasone Phosphate
  • CAS号:312-93-6
  • 分子式:C22H30FO8P
  • 分子量:472.44100
  • 相关类别: 原料药 激素及调节内分泌功能类药 肾上腺皮质激素类药
  • 发布时间:2018-08-12 07:49:32
  • 更新时间:2024-01-02 20:37:17
  • Dexamethasone phosphate (Dexamethasone 21-phosphate) 是一种无生物活性的化合物,可通过红细胞内酶进行去磷酸化。活性代谢物地塞米松随后通过细胞膜的简单被动扩散释放到循环中。Dexamethasone phosphate 包裹的红细胞具有用于类固醇依赖性溃疡性结肠炎研究的潜力。

化源商城直购

中文名 地塞米松磷酸酯
英文名 dexamethasone phosphate
英文别名 Hexadrol phosphate
dexamethasone-21-phosphate
Dexamethasone 21-orthophosphate
Betnelan phosphate
Dexamethasone-21-dihydrogen-phosphate
Wymesone
Neodecadron
Oradexon phosphate
Dexamethasone phosphate
[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate
描述 Dexamethasone phosphate (Dexamethasone 21-phosphate) 是一种无生物活性的化合物,可通过红细胞内酶进行去磷酸化。活性代谢物地塞米松随后通过细胞膜的简单被动扩散释放到循环中。Dexamethasone phosphate 包裹的红细胞具有用于类固醇依赖性溃疡性结肠炎研究的潜力。
相关类别
参考文献

[1]. Fabrizio Bossa, et al. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis. 2013 Aug;19(9):1872-9.  

密度 1.45g/cm3
沸点 669.6ºC at 760mmHg
熔点 154-157°C (lit.)
分子式 C22H30FO8P
分子量 472.44100
闪点 358.7ºC
精确质量 472.16600
PSA 151.17000
LogP 2.01270
外观性状 白色至浅棕色固体
折射率 1.594
储存条件 通风低温干燥

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TU4055000
CHEMICAL NAME :
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-alpha-methyl-, 21-(dihydrogen phosphate)
CAS REGISTRY NUMBER :
312-93-6
LAST UPDATED :
199706
DATA ITEMS CITED :
14
MOLECULAR FORMULA :
C22-H30-F-O8-P
MOLECULAR WEIGHT :
472.49
WISWESSER LINE NOTATION :
L E5 B666 OV AHTTT&J A1 BF CQ E1 FV1OPQQO FQ G1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD - Lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>1 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
36 mg/kg/90D-I
TOXIC EFFECTS :
Endocrine - changes in thymus weight Immunological Including Allergic - decrease in cellular immune response Immunological Including Allergic - decrease in humoral immune response
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
600 ug/kg
SEX/DURATION :
female 21-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - endocrine system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
200 ug/kg
SEX/DURATION :
female 19-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 ug/kg
SEX/DURATION :
female 19-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - hepatobiliary system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
30 mg/kg
SEX/DURATION :
female 8-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
2 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
600 ug/kg
SEX/DURATION :
female 17-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - respiratory system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
600 ug/kg
SEX/DURATION :
female 17-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 mg/kg
SEX/DURATION :
female 14-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 mg/kg
SEX/DURATION :
female 22-25 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

MUTATION DATA

TEST SYSTEM :
Rodent - rat
DOSE/DURATION :
3 mg/kg
REFERENCE :
JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939- Volume(issue)/page/year: 62,527,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3850 No. of Facilities: 130 (estimated) No. of Industries: 3 No. of Occupations: 10 No. of Employees: 5388 (estimated) No. of Female Employees: 2968 (estimated)

危害码 (欧洲) Xn
风险声明 (欧洲) 62
海关编码 2937290090
上游产品  1

下游产品  0

海关编码 2937290090